Although both IL-2cxCD25 and IL-2cxCD122 achieved similar anti-tumor responses in our preclinical model, our data suggest that IL-2cxCD25 preferentially stimulated recently activated intratumoral CD8+ T cells, whereas IL-2cxCD122 expanded antigen-experienced memory CD8+ T cells in both secondary lymphoid organs and the tumor microenvironment. This evidence concerns the gene CD8A and neoplasm.